Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from EQL Pharma AB ( (SE:EQL) ).
EQL Pharma AB announced that two senior executives and one key employee have exercised 466,000 warrants in the company’s incentive programs, resulting in the subscription of 466,000 new shares. This move will bring approximately SEK 31.8 million in cash to the company. To facilitate this transaction, the warrant holders sold 345,642 shares through DNB Carnegie Investment Bank, with a major shareholder lending these shares to them temporarily. The subscription period for the warrant programs remains open until 30 September 2025, allowing further participation.
More about EQL Pharma AB
EQL Pharma AB is a company focused on developing and selling generic drugs, which are medically equivalent to original drugs. They have launched 46 niche generics in the Nordic markets and have a pipeline for future launches. The company operates mainly in the Nordics and European markets, focusing on prescription drugs, including hospital products. EQL Pharma AB is based in Lund and listed on the Nasdaq Stockholm stock market, collaborating with contract manufacturers and pharmaceutical companies in the EU and Asia.
Average Trading Volume: 31,036
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.43B
See more data about EQL stock on TipRanks’ Stock Analysis page.